Security key
H9130A111
Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share (VRXAW)
CUSIP: H9130A111
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Ordinary Shares, par value CHF 100/11325 per share
- Total 13F shares
- 8,886,388
- Total 13F value
- $992,502
- Share change
- +8,633,181
- SEC-reported price per share
- $0.11
- Number of holders
- 26
- Value change
- +$964,573
- Number of buys
- 25
- Shares outstanding
- 141,303,920
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
26
Top holders
10
VRXAW full security history
Ownership snapshot
Full 13F holder table
Veraxa Biotech Holding AG SEC filings
Broader feeds
Ownership snapshot
Top reported holders of VRXAW - Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Deck David Lukas
Disclosed value leader
AQR CAPITAL MANAGEMENT LLC
Comparable rows
5/7
Latest evidence
30 Jun 2026
13D/G
3/4/5
Lead comparable stake: 18%
2 rows are not safely comparable across share classes.
13D/G row: Deck David Lukas
Showing 1-6 of 7 holder rows.
Quick read
Deck David Lukas leads the comparable SEC ownership view at 18%.
5 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Deck David Lukas's linked filing trail.
Comparable ownership
Top 5
Deck David Lukas
18%
Xlife Sciences AG
16%
European Molecular Biology Labora...
16%
Schoeni Gilbert Edgar
16%
AQR CAPITAL MANAGEMENT LLC
0.46%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 7 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Deck David Lukas |
13D/G
|
18%
|
—
25,502,836 shares
|
$0 | 10 Jun 2026 |
| Xlife Sciences AG |
13D/G
|
16%
|
—
23,029,967 shares
|
$0 | 10 Jun 2026 |
| European Molecular Biology Laboratory |
13D/G
|
16%
|
—
22,891,235 shares
|
$0 | 10 Jun 2026 |
| Schoeni Gilbert Edgar |
13D/G
|
16%
|
—
22,539,749 shares
|
$0 | 10 Jun 2026 |
| AQR CAPITAL MANAGEMENT LLC |
13D/G
|
0.46%
|
$1,408,415
658,138 shares
|
$0 | 30 Jun 2026 |
| Warren Hosseinion |
3/4/5
Director
|
—
class O/S missing
|
—
700,000 shares
|
— | 09 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
26
Shares
8,886,388
Rows available
26
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
0
Q2 2026 holders
26
Holder diff
26
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|